Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05494671
Other study ID # N-14-2022
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date November 1, 2023

Study information

Verified date August 2023
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Integrity of the corneal epithelium is the function of intact limbal stem cells. The reduction in the population of LSCs and their dysfunction result in abnormal corneal epithelialization and invasion of the corneal surface by the conjunctival epithelium with or without corneal neovascularization that is, limbal stem cell deficiency (LSCD). Different techniques have been developed to treat cases of limbal stem cell deficiency due to traumatic or congenital cases. Recent innovations developed to predict the early stages of stem cell deficiency. One of these methods is measurement of the central epithelial thickness as it was found that limbal stem cell deficiency causes reduction of the central epithelial thickness. The aim of this study is to study changes in the corneal epithelial thickness at different quadrants of the cornea to observe the exact time of epithelial stability following stem cell transplantation.


Description:

Patients with unilateral chemical ocular injury will be included in the study(12 eyes). All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view. Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU). The patient will be followed up at a week, a month, 3 months, 6months and 9 months postoperative. Corneal epithelial mapping will be done at the previous schedule in both the donated and the recipient eyes using anterior segment OCT (Optical Coherence Tomography) Exclusion criteria: Bilateral cases and patients with severe conjunctival scaring and symblepharon.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date November 1, 2023
Est. primary completion date January 10, 2023
Accepts healthy volunteers No
Gender All
Age group 15 Years to 70 Years
Eligibility Inclusion Criteria: - Patients between 15 to 70 years - Unilateral limbal stem cell deficiency - Grade 4 stem cell deficiency Exclusion Criteria: - Cases with extensive symblepharon - Cases with very poor visual acuity ( no light perception) - Cases with posterior segment problem evident in ocular ultrasonography

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
conjunctival limbal autologous transplant
Patients with unilateral chemical ocular injury will be included in the study. All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view. Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU)

Locations

Country Name City State
Egypt Kasr Alainy Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary the change of corneal epithelial thickness after stem cell transplantation over 9 months Corneal epithelial mapping will be done at one month, 3,6 and 9 months in both the donated and the recipient eyes using anterior segment OCT at the center 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT03918343 - Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation N/A
Not yet recruiting NCT05438823 - Technology Supported Education Program Based on Human Care Theory N/A
Not yet recruiting NCT02193399 - Physiotherapy in Hematopoietic Stem Cell Transplantation N/A
Withdrawn NCT00972101 - Infusion of Expanded Cord Blood T Cells Phase 1
Completed NCT05421299 - A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
Completed NCT04976933 - Post-HSCT Medication Adherence mHealth App
Completed NCT04798495 - Feasibility of a Rehabilitation Programme Targeted Patients Treated With Non-myeloablative Stem Cell Transplantation N/A
Completed NCT00612274 - Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation Phase 0
Active, not recruiting NCT04511130 - Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Phase 2
Recruiting NCT05968963 - Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation N/A
Recruiting NCT02940093 - Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers N/A
Not yet recruiting NCT06077734 - Muscle Stem Cell Quality in Atrophy
Terminated NCT00587990 - Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) Phase 1/Phase 2
Terminated NCT00597441 - Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation Phase 1
Active, not recruiting NCT03684083 - Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients
Recruiting NCT00884338 - Cognitive Function After Stem Cell Transplantation Phase 3
Completed NCT00284713 - Progenitor Cell Therapy in Dilative Cardiomyopathy Phase 1/Phase 2
Withdrawn NCT00062543 - Hepatic Artery Infusion of CD34+ Cells Phase 1
Completed NCT00781170 - Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma Phase 2
Recruiting NCT03364257 - iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients